Adidas faces challenges in North America due to US tariffs and a strong euro, but remains focused on growing its US business through strategic investments and pricing adjustments.
FDA issues draft guidance to streamline biosimilar approvals, aiming to cut bureaucracy and increase competition for lower-cost biologics.
Adidas faces challenges in North America due to US tariffs and a strong euro, but remains focused on growing its US business through strategic investments and pricing adjustments.
FDA issues draft guidance to streamline biosimilar approvals, aiming to cut bureaucracy and increase competition for lower-cost biologics.